#65161
Re: Farmas USA
SNTA
Ganetespib Well Tolerated In Epitelian Ovarian Cancer, Cowen Notes; GALAXY-2 NSCLC Remains in Focus
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Se está hablando de:
#65162
Re: Farmas USA
OCAT
Nueva patente que se suma a las 3 de hace semana y media y afirmación de que tienen patente para todos los productos de células madre pluripotentes para el tratamiento del epitelio pigmentario de la retina
Ocata Therapeutics (OCAT) Issued Patent Related to RPE Therapy for Macular Degenerative Diseases
Ocata recently announced the issuance of three new patents and the Company believes it now has protection for the manufacture of all RPE cell products from pluripotent stem cell sources, including the manufacturing of all formulations, (e.g. suspensions and sheets of cells), for use as therapeutic agents, as well as the use of these formulations for treating ophthalmic diseases, such as dry age related macular degeneration (“dry AMD”) and Stargardt’s macular degeneration (“SMD”).
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#65163
Re: Farmas USA
AMRN
BD a todos.
No veo a los americanos muy contentos con la noticia.
"Buf, se me está haciendo más largo que un dia sin bolsa"
#65164
Re: Farmas USA
con que noticia? Lo de Matinas biopharma? Bah, no problem
AMRN
#65165
Re: Farmas USA
No tenía hoy por la mañana una conferencia con Jefferies? O me equivoco de día...
AMRN
Edito:
2 Jun 2015
8:00 AM ET Jefferies 2015 Global Healthcare Conference
Webcast Listen to webcast
#65166
Re: Farmas USA
#65167
Re: Farmas USA
Dicen en los foros que ha estado muy mal, nervioso, inseguro, preguntando a sus ayudantes antes de hablar de algunas cosas, etc...; vamos, que no están muy convencidos en los foros.
Lo que no sé es de qué conferencia hablan, si de una antigua, o de la nueva.
¿Qué pensais vosotros?
"Buf, se me está haciendo más largo que un dia sin bolsa"
#65168
Re: Farmas USA
CytRx (NASDAQ: CYTR) announced that it has reached an agreement to settle the stockholder derivative action pending in the Delaware Court of Chancery, which names as defendants a number of the Company's current and former directors and officers, and names the Company as a nominal defendant.
The lawsuit, captioned In re CytRx Corp. Stockholder Derivative Litigation, C.A. No. 9864-VCL, relates to the Company's issuance and pricing of stock options to its directors and officers in December 2013. Although the individual defendants have denied any liability or wrongdoing in connection with the allegations contained in the lawsuit, they believe that it is in the best interests of the Company and its stockholders to settle the matter on reasonable terms to avoid potentially protracted and expensive litigation.
The settlement provides that the Company will re-price 2,095,000 stock options that were collectively granted on December 10, 2013 to Louis Ignarro, Joseph Rubinfeld, Marvin L. Selter, Richard L. Wennekamp, Steven A. Kriegsman, John Y. Caloz and Benjamin S. Levin, from the original exercise price of $2.39 to an exercise price of $4.66 (the share price at market closing on December 20, 2013). The settlement also provides that the Company will implement certain corporate governance changes and modify certain governance practices regarding the granting of stock option grants. Under the settlement, it is not expected that the Company will incur any out-of-pocket expenses.
CYTR....
¿Esto debería afectar al precio?